Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Newron Pharmaceuticals SPA clinical trials
The registry lists 31 studies whose lead sponsor is Newron Pharmaceuticals SPA or one of 2 companies grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 10, 2026.
Keep track of what changes. Save the Newron Pharmaceuticals SPA studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Newron Pharmaceuticals SPA.
- Newron Pharmaceuticals SPA22 studiesSame company
Something wrong?
- Newron Sweden AB8 studies →Acquired — became part of Newron Pharmaceuticals SPA, Dec 17, 2012 · source ↗
Something wrong?
- Hunter-Fleming Ltd1 study →Acquired — became part of Newron Pharmaceuticals SPA, 2008 · source ↗
Something wrong?
Focus areas
Conditions Newron Pharmaceuticals SPA leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 31 of 31.
- Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaRecruitingNCT07184619Phase 3
- Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory SymptomsTerminatedNCT02790034Phase 2/3
- Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic SchizophreniaCompletedNCT04461119Phase 2
- An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male SubjectsStatus unknownNCT03446274Phase 1
- Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsTerminatedNCT00865579Phase 3
- A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingTerminatedNCT01264861Phase 2
- Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back PainCompletedNCT01019824Phase 3
- A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.CompletedNCT01955564Phase 1
- A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic SchizophreniaCompletedNCT02624167Phase 2
- Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PDTerminatedNCT02408562Phase 1/2
Sponsor listed in the registry: Newron Sweden AB · First submitted after Newron Sweden AB became part of Newron Pharmaceuticals SPA
- An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisTerminatedNCT01384162Phase 1/2
Sponsor listed in the registry: Newron Sweden AB · First submitted before Newron Sweden AB became part of Newron Pharmaceuticals SPA
- A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.TerminatedNCT01829867Phase 1
Sponsor listed in the registry: Newron Sweden AB · First submitted after Newron Sweden AB became part of Newron Pharmaceuticals SPA
- A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALSTerminatedNCT01999803Phase 1
Sponsor listed in the registry: Newron Sweden AB · First submitted after Newron Sweden AB became part of Newron Pharmaceuticals SPA
- A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALSTerminatedNCT02269436Phase 1
Sponsor listed in the registry: Newron Sweden AB · First submitted after Newron Sweden AB became part of Newron Pharmaceuticals SPA
- A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseCompletedNCT00866502Phase 1/2
Sponsor listed in the registry: Newron Sweden AB · First submitted before Newron Sweden AB became part of Newron Pharmaceuticals SPA
- A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseCompletedNCT01807338
Sponsor listed in the registry: Newron Sweden AB · First submitted after Newron Sweden AB became part of Newron Pharmaceuticals SPA
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistCompletedNCT00605683Phase 3
- Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsCompletedNCT01113320Phase 2
- Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaCompletedNCT00627640Phase 3
- MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)TerminatedNCT01028586Phase 3
- A Study to Assess the Effect of Hepatic Impairment on Safinamide PharmacokineticsCompletedNCT01027169Phase 1
- Safinamide Renal Impairment TrialCompletedNCT01374113Phase 1
- A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseCompletedNCT01211587Phase 2
- A Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsCompletedNCT01026428Phase 1/2
- A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisCompletedNCT00800501Phase 1/2
Sponsor listed in the registry: Newron Sweden AB · First submitted before Newron Sweden AB became part of Newron Pharmaceuticals SPA
- 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDCompletedNCT01286935Phase 3
- Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseaseCompletedNCT01187966Phase 3
- Phase II Dose Titration Study in Patients With Neuropathic PainCompletedNCT00736151Phase 2
- European Study of HF0220 in Mild to Moderate Alzheimer's Disease PatientsCompletedNCT00357357Phase 2
Sponsor listed in the registry: Hunter-Fleming Ltd · First submitted before Hunter-Fleming Ltd became part of Newron Pharmaceuticals SPA
- Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)CompletedNCT00642889Phase 3
- Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistCompletedNCT00643045Phase 3